The country’s first fully ingenuously developed vaccine against pneumonia has got approval from the Drug Controller General of India (DCGI). The vaccine is administered in an intramuscular manner. The ministry said the vaccine will be used for active immunization against invasive disease and pneumonia caused by ‘Streptococcus pneumonia’ among infants.
The Serum Institute of India first obtained the approval of the DCGI to conduct Phase I, II and III clinical trials of the vaccine in India. These trials have since been concluded within the country. The company also conducted the clinical trials in Gambia. On July 14, Serum Institute of India Pvt Ltd was granted permission to manufacture domestically developed first Pneumococcal Polyacrylamide Conjugate Vaccine, the ministry said.